- Home
- PETS vs AVTX Comparison
PETS vs AVTX Comparison
Compare PETS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- AVTX
- Stock Information
- Founded
- PETS 1996
- AVTX 2011
- Country
- PETS United States
- AVTX United States
- Employees
- PETS N/A
- AVTX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- AVTX Health Care
- Exchange
- PETS Nasdaq
- AVTX Nasdaq
- Market Cap
- PETS 62.8M
- AVTX 57.4M
- IPO Year
- PETS N/A
- AVTX 2015
- Fundamental
- Price
- PETS $3.74
- AVTX $3.94
- Analyst Decision
- PETS Sell
- AVTX Strong Buy
- Analyst Count
- PETS 2
- AVTX 6
- Target Price
- PETS $3.35
- AVTX $34.20
- AVG Volume (30 Days)
- PETS 111.3K
- AVTX 62.6K
- Earning Date
- PETS 06-10-2025
- AVTX 05-12-2025
- Dividend Yield
- PETS N/A
- AVTX N/A
- EPS Growth
- PETS N/A
- AVTX N/A
- EPS
- PETS 0.02
- AVTX N/A
- Revenue
- PETS $247,010,000.00
- AVTX $441,000.00
- Revenue This Year
- PETS N/A
- AVTX N/A
- Revenue Next Year
- PETS N/A
- AVTX N/A
- P/E Ratio
- PETS $216.83
- AVTX $0.59
- Revenue Growth
- PETS N/A
- AVTX N/A
- 52 Week Low
- PETS $2.90
- AVTX $3.39
- 52 Week High
- PETS $6.85
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- PETS 48.08
- AVTX 45.63
- Support Level
- PETS $3.56
- AVTX $3.43
- Resistance Level
- PETS $3.82
- AVTX $4.03
- Average True Range (ATR)
- PETS 0.18
- AVTX 0.34
- MACD
- PETS -0.01
- AVTX 0.09
- Stochastic Oscillator
- PETS 15.83
- AVTX 70.47
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).